This is a brief summary of abstracts presented at the 2013 GI ASCO meeting. Please note that abstracts have not been through a complete peer review process and are considered to be preliminary.
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Since we have gotten a number of questions about Gleevec (imatinib) plasma levels and testing, I think it’s time to revisit the subject, especially for newer members. Since this is a very complex subject, this may take a few emails and a few days.
Sutent is the second-line approved treatment for Gastrointestinal Stromal Tumor and is prescribed when treatment with the first-line drug, Gleevec (Imatinib) is no longer effective or cannot be tolerated. The two drugs work differently, so [...]
The Sarcoma Alliance for Research through Collaboration (SARC) in partnership with the National Cancer Institute (NCI) is currently recruiting patients for its Phase II trial (SARC-022) of Linsitinib (OSI-906), an IGF-1R inhibitor. Linsitinib is targeted [...]
Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).
The Life Raft Group surveyed patients and physicians about dosing options for the drug Sutent (sunitinib) to follow up on a 2011 study that showed that patients on a continuous dose exhibited better clinical outcomes than those on the standard four-week on, two-week off dosing regimen.